First, the cross-sectional design has precluded the possibility of exploring the temporal trend of plasma PCSK9 levels depending on the introduction of corticosteroids/immunomodulators as well as on concomitant modifications in pSS disease activity. This evidence concerns the gene PCSK9 and peeling skin syndrome.